Abstract
In the past 10 years, progress has been made in the management of patients with chronic hepatitis C. A sustained virological response (SVR) is achieved in 80-85% of patients infected with hepatitis C virus (HCV) genotype 2 or 3 after 24 weeks of treatment with peginterferon-α and ribavirin. Treatment durations
Original language | English |
---|---|
Pages (from-to) | 1807-1815 |
Number of pages | 9 |
Journal | Drugs |
Volume | 66 |
Issue number | 14 |
DOIs | |
Publication status | Published - 2006 |
ASJC Scopus subject areas
- Toxicology
- Health, Toxicology and Mutagenesis